Former Bristol-Myers Squibb ($BMY) R&D chief Elliott Sigal is making the leap into venture capital. Sigal is joining New Enterprise Associates, where former MedImmune CEO David Mott has been leading the healthcare crew. Report
Former Bristol-Myers Squibb ($BMY) R&D chief Elliott Sigal is making the leap into venture capital. Sigal is joining New Enterprise Associates, where former MedImmune CEO David Mott has been leading the healthcare crew. Report